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Granulocyte colonyestimulating factor (G-CSF) increases the susceptibility of dormant malignant or
nonmalignant hematopoietic cells to cytarabine arabinoside (Ara-C) through the induction of cell cycle
entry. Therefore, G-CSFecombined conditioning before allogeneic stem cell transplantation might
positively contribute to decreased incidences of relapse and graft failure without having to increase the
dose of cytotoxic drugs. We conducted a retrospective nationwide study of 336 adult patients with
myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML) after single-unit cord
blood transplantation (CBT) who underwent 4 different kinds of conditioning regimens: total body
irradiation (TBI)  8 Gy þ Ara-C/G-CSF þ cyclophosphamide (CY) (n ¼ 65), TBI  8 Gy þ Ara-C þ CY
(n¼ 119), TBI 8 Gyþ other (n¼ 104), or TBI< 8 Gy or non-TBI (n¼ 48). The TBI 8 Gyþ Ara-C/G-CSFþ CY
regimen showed signiﬁcantly higher incidence of neutrophil engraftment (hazard ratio, 1.52; 95% conﬁ-
dence interval [CI], 1.10 to 2.08; P ¼ .009) and lower overall mortality (hazard ratio, .46; 95% CI, .26 to .82;
P ¼ .008) rates compared with those without a G-CSF regimen. This retrospective study shows that theedgments on page 1639.
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T. Konuma et al. / Biol Blood Marrow Transplant 21 (2015) 1632e1640 1633G-CSFecombined conditioning regimen provides better engraftment and survival results in CBT for adults
with MDS and sAML.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) provides
the only chance for long-term survival for patients with
myelodysplastic syndrome (MDS) and secondary acute
myeloid leukemia (sAML) arisen from MDS [1,2]. Cord blood
from an unrelated donor has been considered an acceptable
alternative graft source in allo-SCT for patients without a
human leukocyte antigen (HLA)ecompatible related or un-
related donor [3-8]. Although intensiﬁed conditioning
regimens have been used to decrease the incidence of relapse
in high-risk patients who received allo-SCT using adult do-
nors [9-12], whether the use of an intensiﬁed conditioning
regimenmight overcome the higher incidence of graft failure
after cord blood transplantation (CBT) remains unclear.
The administration of granulocyte colonyestimulating
factor (G-CSF) increases the susceptibility of leukemia cells
to the cell cycleespeciﬁc agent cytarabine in vitro [13].
Although the priming effect of G-CSF during induction
chemotherapy for AML is controversial [14], several studies
have reported that the concomitant use of G-CSF and cytar-
abine arabinoside (Ara-C) during induction chemotherapy
led to signiﬁcantly better survival for patients with newly
diagnosed AML [15-17]. Furthermore, the administration of
G-CSF before irradiation enhanced engraftment of donor
cells in a mouse bone marrow transplantation model [18,19].
Therefore, G-CSFecombined conditioning might contribute
to decreased incidences of relapse and graft failure without
increasing the dose of cytotoxic drugs.
We previously reported that the addition of G-CSFecom-
bined Ara-C to a total body irradiation (TBI) and cyclophospha-
mide (CY) conditioning regimen led to a signiﬁcantly higher
incidence of neutrophil engraftment and signiﬁcantly better
survival in CBT in de novo AML [20]. The conditioning regimen
originally consisted of Ara-C (total dose 12 g/m2; 3 g/m2 every
12 hours for 2 days) with 5 mg/kg G-CSF (lenograstim) from 12
hours before the ﬁrst dose of cytarabine to the end of the
cytarabine dosing, and TBI 12 Gy and CY (total dose 120mg/kg),
which has been described previously [5,6]. However, there has
been no comparative study of the transplantation outcomes for
MDS and sAML after CBT following a conditioning regimenwith
or without G-CSF. Therefore, to determine the role of a G-CSF
combination in a conditioning regimen before CBT in MDS and
sAML patients, we conducted a retrospective nationwide study
of 336 adult patients with MDS and sAML in Japan.PATIENTS AND METHODS
Study Design and Data Collection
The clinical data were provided by the Transplant Registry Uniﬁed
Management Program (TRUMP) of the Japan Society of Hematopoietic Cell
Transplantation [21]. This retrospective study included patients who ranged
from 16 to 55 years of age at the time of CBT, who had MDS or sAML, who
received single-unit CBT without a prior transplantation history, and who
underwent a myeloablative conditioning regimen before CBT. The diagnosis
of AML or MDS was made according to the French-American-British clas-
siﬁcation. We deﬁned sAML as AML arisen from MDS. Patients with a
diagnosis of chronic myelomonocytic leukemia were excluded from this
study. CBTs were performed between July 1998 and December 2012 in
Japan. The institutional review board of the Institute of Medical Science,
University of Tokyo, approved this study. This study was conducted in
accordance with the Declaration of Helsinki.Endpoints and Deﬁnitions
The study endpoints were neutrophil and platelet engraftment,
transplantation-related mortality (TRM), relapse, disease-free survival
(DFS), and overall survival (OS). Neutrophil engraftmentwas deﬁned as being
achieved on the ﬁrst of 3 consecutive days during which the absolute
neutrophil count was at least .5  109/L. Platelet engraftment was deﬁned as
being achieved on the ﬁrst of 3 consecutive days when the platelet count
was higher than 20 109/L without transfusion support. TRMwas deﬁned as
death during remission. Relapse was deﬁned as evidence of disease in the
peripheral blood, bone marrow, or extramedullary sites. Patients who never
achieved remission after CBT were considered to have had a relapse on day
1. The DFS (inverse of treatment failure) was deﬁned as the time from the
date of CBT to the date of relapse, death in continuous complete remission,
or last contact. The OS (inverse of overall mortality) was deﬁned as the time
from the date of CBT to the date of death or last contact.
The myeloablative conditioning regimen was deﬁned according to the
Center for International Blood andMarrow Transplant Research criteria [22].
The conditioning regimen was categorized as 1 of 4 different myeloablative
regimens: TBI  8 Gy þ Ara-C/G-CSF þ CY, TBI  8 Gy þ Ara-C þ CY, TBI  8
Gy þ other, or TBI < 8 Gy or non-TBI. Cytogenetic risk was classiﬁed ac-
cording to the International Prognostic Scoring System criteria [23],
althoughwewere unable to use the International Prognostic Scoring System
components at diagnosis because of insufﬁcient data in the TRUMP. Because
HLA-DR mismatches were previously evaluated at the low-resolution level
at cord blood unit selection in Japan [24], data regarding HLA-DRB1 allele
informationwere not fully available in the TRUMP. Therefore, the number of
HLA disparities was deﬁned as a low-resolution for HLA-A, -B, and -DR in the
graft-versus-host direction. All patients were administered G-CSF after CBT
to shorten the duration of neutropenia.Statistical Analysis
The baseline patient and transplantation characteristics were compared
using the chi-square test or Fisher’s exact test for categorical variables. The
probabilities of DFS and OS were estimated according to the Kaplan-Meier
method and the groups were compared using the log-rank test. The prob-
abilities of neutrophil and platelet engraftment, TRM, and relapse were
estimated based on a cumulative incidence method to accommodate
competing risks. A multivariate analysis was performed with a Cox pro-
portional hazard model adjusted for the DFS and OS, and a Fine and Gray
proportional hazards model was used for the other analyses. The following
variables were considered: conditioning regimen, age (<45 versus 45
years), recipients’ cytomegalovirus serostatus (positive versus negative), the
etiology of MDS (de novo versus secondary), cytogenetic risk at diagnosis
(favorable versus intermediate versus poor), prior chemotherapy before CBT
(no versus yes), the interval from diagnosis to CBT (<6 months versus 6
months), the status of French-American-British classiﬁcation at CBT
(refractory anemia/refractory anemia with ringed sideroblasts versus re-
fractory anemia with excess blasts versus refractory anemia with excess
blastsetransformed versus sAML), bone marrow blasts at CBT (<5% versus
5%), cord blood nucleated cell count (<2.5  107/kg versus 2.5  107/kg),
cord blood CD34þ cell count (<1 105/kg versus1 105/kg), graft-versus-
host disease prophylaxis (cyclosporine-based versus tacrolimus-based), HLA
disparities (0 versus 1 versus 2 versus 3), donor-recipient ABO compati-
bility (match versus mismatch), and year of CBT (1998 to 2006 versus 2007
to 2012). In this study, the TBI 8 Gyþ Ara-Cþ CYgroupwas considered the
reference group according to multivariate analyses, because the main pur-
pose of this study was to evaluate the additional effects of G-CSF in a TBI 8
Gy þ Ara-C þ CY conditioning regimen. Final model variables were
conﬁrmedwith a backward selection procedure at the level of signiﬁcance of
P ¼ .05. All P values were 2 sided. All statistical analyses were performed
with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan),
a graphical user interface for the R 3.0.2 software program (R Foundation for
Statistical Computing, Vienna, Austria) [25].RESULTS
Characteristics of Patients and Grafts
The characteristics of the patients and cord blood units
are shown in Table 1. Three hundred thirty-six patients (199
Table 1
Characteristics of the Patients, Cord Blood Units, and Transplantation
Characteristic Total TBI  8 Gy þ
Ara-C/G-CSF þ CY
TBI  8 Gy þ
Ara-C þ CY
TBI  8 Gy þ
Other
TBI < 8 Gy
or Non-TBI
P Value
No. of patients 336 65 (19%) 119 (35%) 104 (30%) 48 (14%)
Age at CBT .03
16-44 yrs 183 (54%) 42 (64%) 71 (59%) 49 (47%) 21 (43%)
45-55 yrs 153 (45%) 23 (35%) 48 (40%) 55 (52%) 27 (56%)
Sex .24
Male 196 (58%) 43 (66%) 65 (54%) 64 (61%) 24 (50%)
Female 140 (41%) 22 (33%) 54 (45%) 40 (38%) 24 (50%)
CMV serostatus .97
Positive 258 (76%) 51 (78%) 95 (79%) 77 (74%) 35 (72%)
Negative 50 (14%) 10 (15%) 18 (15%) 14 (13%) 8 (16%)
Missing 28 (8%) 4 (6%) 6 (5%) 13 (12%) 5 (10%)
Etiology .78
De novo MDS 288 (85%) 58 (89%) 104 (87%) 86 (85%) 40 (83%)
Secondary MDS 45 (13%) 7 (10%) 15 (12%) 15 (14%) 8 (16%)
Missing 3 (<1%) 0 0 3 (2%) 0
Cytogenetics .24
Favorable 119 (35%) 26 (40%) 44 (36%) 35 (33%) 14 (29%)
Intermediate 87 (25%) 12 (18%) 40 (33%) 23 (22%) 12 (25%)
Poor 114 (33%) 23 (35%) 33 (27%) 38 (36%) 20 (41%)
Missing 16 (4%) 4 (6%) 2 (1%) 8 (7%) 2 (4%)
FAB classiﬁcation at CBT .07
RA/RARS 45 (13%) 8 (12%) 19 (15%) 10 (9%) 8 (16%)
RAEB 109 (32%) 16 (24%) 49 (41%) 31 (29%) 13 (27%)
RAEB-t 30 (8%) 3 (6%) 12 (10%) 13 (12%) 2 (4%)
sAML 137 (40%) 35 (53%) 39 (32%) 41 (39%) 22 (45%)
Missing 15 (4%) 3 (4%) 0 9 (8%) 3 (6%)
Bone marrow blasts at CBT .98
<5% 80 (23%) 15 (23%) 31 (26%) 23 (22%) 11 (22%)
5% 234 (69%) 48 (73%) 87 (73%) 67 (64%) 32 (66%)
Missing 22 (6%) 2 (3%) 1 (<1%) 14 (13%) 5 (10%)
Time from diagnosis to CBT .23
<6 mo 122 (36%) 19 (29%) 51 (42%) 32 (30%) 20 (41%)
6 mo 167 (49%) 40 (61%) 54 (45%) 47 (45%) 26 (54%)
Missing 47 (13%) 6 (9%) 14 (11%) 25 (24%) 2 (4%)
Previous chemotherapy .37
No 163 (48%) 34 (52%) 66 (55%) 44 (42%) 19 (39%)
Yes 155 (46%) 29 (44%) 52 (43%) 48 (46%) 26 (54%)
Missing 18 (5%) 2 (3%) 1 (<1%) 12 (11%) 3 (6%)
Year of CBT <.001
1998-2006 132 (39%) 34 (52%) 39 (32%) 52 (50%) 7 (14%)
2007-2012 204 (60%) 31 (47%) 80 (67%) 52 (50%) 41 (85%)
No. of nucleated cells .09
<2.5  107/kg 169 (50%) 33 (50%) 69 (57%) 50 (48%) 17 (35%)
2.5  107/kg 160 (47%) 32 (49%) 49 (41%) 50 (48%) 29 (60%)
Missing 7 (2%) 0 1 (<1%) 4 (3%) 2 (4%)
No. of CD34þcells .97
<1  105/kg 199 (59%) 40 (61%) 70 (58%) 61 (58%) 28 (58%)
1  105/kg 127 (37%) 24 (36%) 47 (39%) 37 (35%) 19 (39%)
Missing 10 (2%) 1 (1%) 2 (1%) 6 (5%) 1 (2%)
HLA disparities .42
0 33 (9%) 7 (10%) 7 (5%) 14 (13%) 5 (10%)
1 101 (30%) 17 (26%) 33 (27%) 38 (36%) 13 (27%)
2 175 (52%) 34 (52%) 68 (57%) 46 (44%) 27 (56%)
3 27 (8%) 7 (10%) 11 (9%) 6 (5%) 3 (6%)
ABO incompatibility .13
Match 117 (34%) 18 (27%) 46 (38%) 32 (30%) 21 (43%)
Minor mismatch 92 (27%) 22 (33%) 23 (19%) 34 (32%) 13 (27%)
Major mismatch 81 (24%) 13 (20%) 33 (27%) 23 (22%) 12 (25%)
Bidirectional mismatch 46 (13%) 12 (18%) 17 (14%) 15 (14%) 2 (4%)
GVHD prophylaxis <.001
Cyclosporine-based 188 (55%) 60 (92%) 65 (54%) 50 (48%) 13 (27%)
Tacrolimus-based 148 (44%) 5 (7%) 54 (45%) 54 (51%) 35 (72%)
G-CSF administration
after CBT
1.00
Yes 320 (95%) 64 (98%) 112 (94%) 99 (95%) 45 (93%)
No 0 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Missing 16 (4%) 1 (1%) 7 (5%) 5 (4%) 3 (6%)
CMV indicates cytomegalovirus; FAB, French-American-British; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory
anemia with excess blasts; REAB-t, refractory anemia with excess blastsetransformed; GVHD, graft-versus-host disease.
T. Konuma et al. / Biol Blood Marrow Transplant 21 (2015) 1632e16401634MDS and 137 sAML) were eligible for this study. Among the
entire cohort, the median age was 43 (range, 16 to 55) years
old, themedian number of cryopreserved nucleated cells was2.47  107/kg (range, .02  107/kg to 5.92  107/kg), and the
median number of cryopreserved CD34þ cells was .82 
105/kg (range, .01 105/kg to 21.61 105/kg). There were no
Figure 1. The cumulative incidences of neutrophil (A) and platelet recovery
(B) after cord blood transplantation according to the conditioning regimen.
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except for the following: the proportion of patients who
were 45 years of age or older at CBT was lower in the
intensiﬁed regimens (TBI  8 Gyþ Ara-C/G-CSFþ CYand TBI
 8 Gy þ Ara-C þ CY). Cyclosporine-based graft-versus-host
disease prophylaxis was more frequently used in the TBI  8
Gy þ Ara-C/G-CSF þ CY group compared with the other
groups. CBTs of the TBI  8 Gy þ Ara-C þ CY and the TBI < 8
Gy or non-TBI group were more frequently performed in
recent years. The median follow-up period for the survivors
(n ¼ 159) in the entire cohort was 43 months (range, 2 to
168) after CBT.
Neutrophil and Platelet Engraftment
The cumulative incidence of neutrophil recovery signif-
icantly differed among the 4 groups according to a univar-
iate analysis (P ¼ .005). The cumulative incidence of
neutrophil recovery 30 days after CBT was 84% (95%
conﬁdence interval [CI], 72% to 91%) in the TBI 8 Gy þ Ara-
C/G-CSF þ CY group, 72% (95% CI, 63% to 79%) in the TBI  8
Gy þ Ara-C þ CY group, 56% (95% CI, 46% to 65%) in the TBI
8 Gy þ other group, and 58% (95% CI, 43% to 71%) in the TBI
< 8 Gy or non-TBI group (Figure 1A). In the multivariate
analysis, the hazard risk of the ﬁnal model for neutrophil
engraftment was signiﬁcantly higher in the TBI  8 Gy þ
Ara-C/G-CSF þ CY group (P ¼ .009) compared with the TBI 
8 Gy þ Ara-C þ CY group (Table 2). Among the patients
achieving neutrophil engraftment, the neutrophil recovery
times were not signiﬁcantly different among the 4 groups
(P ¼ .76).
The cumulative incidence of platelet recovery signiﬁ-
cantly differed among the 4 groups in univariate analysis
(P ¼ .003). The cumulative incidence of platelet recovery 100
days after CBT was 88% (95% CI, 75% to 94%) in the TBI  8
Gyþ Ara-C/G-CSFþ CYgroup, 75% (95% CI, 65% to 83%) in the
TBI  8 Gy þ Ara-C þ CY group, 56% (95% CI, 45% to 66%) in
the TBI 8 Gyþ other group, and 64% (95% CI, 45% to 78%) in
the TBI < 8 Gy or non-TBI group (Figure 1B). In multivariate
analysis, a trend towards a higher incidence of platelet
engraftment was observed in the TBI 8 Gyþ Ara-C/G-CSFþ
CY group compared with the TBI  8 Gy þ Ara-C þ CY group,
but this was not signiﬁcant in the multivariate analysis
(P ¼ .08) (Table 2). Among the patients achieving platelet
engraftment, the platelet recovery times were not signiﬁ-
cantly different among the 4 groups (P ¼ .29).
TRM
The cumulative incidence of TRM signiﬁcantly differed
among the 4 groups in univariate analysis (P ¼ .007). The
cumulative incidence of TRM at 3 years was 11% (95% CI, 4%
to 20%) in the TBI  8 Gy þ Ara-C/G-CSF þ CY group, 22%
(95% CI, 15% to 30%) in the TBI  8 Gy þ Ara-C þ CY group,
27% (95% CI, 19% to 36%) in the TBI 8 Gyþ other group, and
37% (95% CI, 23% to 51%) in the TBI < 8 Gy or non-TBI group
(Figure 2A). In multivariate analysis, compared with the TBI
 8 Gy þ Ara-C þ CY group, the hazard risk of the ﬁnal
model for TRM was signiﬁcantly lower in the TBI  8 Gy þ
Ara-C/G-CSF þ CY group (P ¼ .03), but it was higher in the
TBI < 8 Gy or non-TBI group (P ¼ .01) (Table 2).
Relapse
The cumulative incidence of relapse at 3 years did not
differ signiﬁcantly among the 4 groups in univariate analysis
(P ¼ .31). The cumulative incidence of relapse at 3 years was
25% (95% CI, 15% to 36%) in the TBI  8 Gy þ Ara-C/G-CSF þCY group, 36% (95% CI, 27% to 45%) in the TBI  8 Gy þ Ara-
C þ CY group, 38% (95% CI, 29% to 48%) in the TBI  8 Gy þ
other group, and 33% (95% CI, 18% to 49%) in the TBI< 8 Gy or
non-TBI group (Figure 2B). The multivariate analysis of
relapse showed no signiﬁcant differences between the TBI 
8 Gyþ Ara-Cþ CYgroup and the TBI 8 Gyþ Ara-C/G-CSFþ
CY group (P ¼ .64), TBI  8 Gy þ other group (P ¼ .48), or TBI
< 8 Gy or non-TBI group (P ¼ .08) (Table 2).
DFS and OS
Among the patients in the entire cohort, the probabilities
of DFS and OS at 3 years inwere 41% (95% CI, 36% to 47%) and
44% (95% CI, 39% to 50%), respectively. The probability of DFS
at 3 years differed signiﬁcantly among the 4 groups in the
univariate analysis (P < .001) (Figure 3A). The probability of
DFS at 3 years was 63% (95% CI, 50% to 74%) for the TBI  8
Gy þ Ara-C/G-CSF þ CY group, 41% (95% CI, 32% to 50%) for
the TBI  8 Gy þ Ara-C þ CY group, 33% (95% CI, 24% to 42%)
for the TBI 8 Gyþ other group, and 29% (95% CI,15% to 44%)
for the TBI < 8 Gy or non-TBI group. In multivariate analysis,
compared with the TBI  8 Gy þ Ara-C þ CY group, the
hazard risk of the ﬁnal model for treatment failure was
signiﬁcantly lower in the TBI  8 Gy þ Ara-C/G-CSF þ CY
group (P ¼ .01) (Table 2).
Table 2
Results of the Multivariate Analysis of Transplantation Outcomes
Outcomes No. of Patients HR (95% CI) P Value
Neutrophil engraftment
Conditioning regimen
TBI  8 Gy þ Ara-C þ CY 119 1 Reference
TBI  8 Gy þ Ara-C/G-CSF þ CY 65 1.52 (1.10-2.08) .009
TBI  8 Gy þ other 104 .66 (.44-1.01) .05
TBI < 8 Gy þ other or non-TBI 48 .92 (.56-1.50) .74
FAB classiﬁcation at CBT
RA/RARS 45 1 Reference
RAEB 109 .59 (.37-.93) .02
RAEB-t 30 1.11 (.64-1.91) .70
sAML 137 .83 (.53-1.29) .42
Time from diagnosis to CBT
<6 mo 122 1 Reference
6 mo 167 .61 (.45-.81) <.001
No. of CD34þcells
1  105/kg 199 1 Reference
<1  105/kg 127 .60 (.45-.80) <.001
Year of CBT
2007-2012 204 1 Reference
1998-2006 132 .70 (.51-.95) .02
Platelet engraftment
Conditioning regimen
TBI  8 Gy þ Ara-C þ CY 119 1 Reference
TBI  8 Gy þ Ara-C/G-CSF þ CY 65 1.35 (.95-1.92) .08
TBI  8 Gy þ other 104 .69 (.44-1.06) .09
TBI < 8 Gy þ other or non-TBI 48 .59 (.35-1.00) .05
Cytogenetics
Favorable 119 1 Reference
Intermediate 87 .84 (.58-1.22) .37
Poor 114 .56 (.38-.81) .002
Previous chemotherapy
No 163 1 Reference
Yes 155 .70 (.51-.95) .02
Transplantation-related mortality
Conditioning regimen
TBI  8 Gy þ Ara-C þ CY 119 1 Reference
TBI  8 Gy þ Ara-C/G-CSF þ CY 65 .33 (.12-.92) .03
TBI  8 Gy þ other 104 1.21 (.59-2.48) .59
TBI < 8 Gy þ other or non-TBI 48 2.38 (1.18-4.81) .01
Year of CBT
2007-2012 204 1 Reference
1998-2006 132 1.93 (1.00-3.71) .04
Relapse
Conditioning regimen
TBI  8 Gy þ Ara-C þ CY 119 1 Reference
TBI  8 Gy þ Ara-C/G-CSF þ CY 65 1.19 (.56-2.54) .64
TBI  8 Gy þ other 104 1.23 (.68-2.22) .48
TBI < 8 Gy þ other or non-TBI 48 .47 (.20-1.11) .08
Bone marrow blasts at CBT
<5% 80 1 Reference
5% 234 2.11 (1.17-3.79) .01
GVHD prophylaxis
Cyclosporine-based 188 1 Reference
Tacrolimus-based 148 1.67 (1.08-2.60) .02
Treatment failure
Conditioning regimen
TBI  8 Gy þ Ara-C þ CY 119 1 Reference
TBI  8 Gy þ Ara-C/G-CSF þ CY 65 .49 (.29-.85) .01
TBI  8 Gy þ other 104 1.41 (.91-2.18) .11
TBI < 8 Gy þ other or non-TBI 48 1.19 (.71-1.98) .50
Bone marrow blasts at CBT
<5% 80 1 Reference
5% 234 1.96 (1.24-3.10) .003
Previous chemotherapy
No 163 1 Reference
Yes 155 1.56 (1.07-2.26) .01
Overall mortality
Conditioning regimen
TBI  8 Gy þ Ara-C þ CY 119 1 Reference
TBI  8 Gy þ Ara-C/G-CSF þ CY 65 .46 (.26-.82) .008
TBI  8 Gy þ other 104 1.33 (.85-2.10) .20
TBI < 8 Gy þ other or non-TBI 48 1.29 (.75-2.21) .34
(Continued on next page)
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Table 2
(continued)
Outcomes No. of Patients HR (95% CI) P Value
Bone marrow blasts at CBT
<5% 80 1 Reference
5% 234 2.20 (1.34-3.59) .001
Previous chemotherapy
No 163 1 Reference
Yes 155 1.79 (1.22-2.64) .002
HR indicates hazard ratio.
Variables considered in multivariate analysis were conditioning regimen, age, recipients’ cytomegalovirus serostatus, the etiology of MDS, cytogenetic risk at
diagnosis, prior chemotherapy before CBT, the interval from diagnosis to CBT, the status of FAB classiﬁcation at CBT, bone marrow blasts at CBT, cord blood
nucleated cell count, cord blood CD34þ cell count, GVHD prophylaxis, HLA disparities, donor-recipient ABO compatibility, and year of CBT. The only signiﬁcant
variables other than conditioning regimen were described in each endpoint.
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among the 4 groups in univariate analysis (P < .001)
(Figure 3B). The probability of OS at 3 years was 66% (95% CI,
53% to 76%) for the TBI 8 Gyþ Ara-C/G-CSFþ CYgroup, 46%
(95% CI, 36% to 55%) for the TBI  8 Gy þ Ara-C þ CY group,
34% (95% CI, 25% to 44%) for the TBI  8 Gy þ other group,
and 36% (95% CI, 21% to 50%) for the TBI < 8 Gy or non-TBI
group. In multivariate analysis, the hazard risk of the ﬁnal
model for overall mortality was signiﬁcantly lower in the TBIFigure 2. The cumulative incidences of transplant-related mortality (A) and
relapse (B) after cord blood transplantation according to the conditioning
regimen. 8 Gy þ Ara-C/G-CSF þ CY group (P ¼ .008) compared with
the TBI  8 Gy þ Ara-C þ CY group (Table 2).
Causes of Death
The major cause of death in all groups was disease
relapse. The proportion of TRM was the lowest in the TBI  8
Gy þ Ara-C/G-CSF þ CY group. In fact, although the pro-
portions of infection and organ failure were closely similar in
all groups, no patients died of graft failure and hemorrhage in
the TBI  8 Gy þ Ara-C/G-CSF þ CY group (Table 3).Figure 3. The probabilities of disease-free survival (A) and overall survival (B)
after cord blood transplantation according to the conditioning regimen.
Table 3
Causes of Death
Cause of Death Total TBI  8 Gy þAra-C/G-CSF þ CY TBI  8 Gy þAra-C þ CY TBI  8 Gy þ Other TBI < 8 Gy or Non-TBI
Total no. 177 22 61 65 29
Relapse 62 (35%) 10 (45%) 20 (32%) 25 (38%) 7 (24%)
TRM 114 (64%) 12 (54%) 41 (67%) 40 (61%) 22 (75%)
Infection 32 (18%) 5 (22%) 8 (13%) 13 (20%) 6 (20%)
Organ failure 32 (18%) 3 (13%) 14 (22%) 10 (15%) 5 (17%)
GVHD 11 (6%) 3 (13%) 2 (3%) 3 (4%) 3 (10%)
Intestinal pneumonia 5 (2%) 0 1 (1%) 2 (3%) 2 (6%)
Hemorrhage 15 (8%) 0 7 (11%) 5 (7%) 3 (10%)
Graft failure 18 (10%) 0 9 (14%) 6 (9%) 3 (10%)
Other 2 (1%) 1 (4%) 0 1 (1%) 0
Data presented are n (%), unless otherwise indicated.
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The aim of this retrospective study was to determine the
effect of the addition of G-CSF in a conditioning regimen for
CBT in adult patients with MDS and sAML. In our study, the
G-CSFecombined regimen enhanced the incidence of
neutrophil engraftment, resulting in lower TRM compared
with the other conditioning regimens without G-CSF. Similar
to our previous report on CBT for de novo AML [20], the
G-CSFecombined regimen signiﬁcantly improved survival
for adult patients with MDS and sAML.
CBT has been established as an alternative approach in
allo-SCT for patients lacking an HLA-identical related or
unrelated donor. However, the reports of disease-speciﬁc
outcomes for adult patients with MDS and sAML after CBT
have been limited [26,27]. A European Group for Blood and
Marrow Transplantation analysis by Robin et al. reported the
outcome of CBT in 108 adult patients with MDS and sAML
[26]. They showed that the probability of OS and the cumu-
lative incidences of relapse and TRM at 2 years were 34%,
21%, and 49%, respectively. In multivariate analysis, a higher
disease risk at CBT was associated with a lower DFS. How-
ever, this study included the results of transplantation of
both single and double cord blood grafts, and it did not
describe the intensity of the conditioning regimens in detail.
Our present study included a large population of adult
patients with MDS and sAML who received single-unit CBT,
and so the effect of the conditioning regimen in single-unit
CBT could be evaluated.
Intensiﬁed conditioning has been analyzed to reduce the
risk of relapse, particularly in high-risk AML [9-12]. However,
most of the studies demonstrated no beneﬁcial effect of
intensiﬁed conditioning, possibly because of the earlier
study period (more than 1 decade ago). Although these
studies analyzed patients receiving bone marrow or mobi-
lized peripheral blood as a graft source from related and
unrelated donors, the optimal conditioning regimen before
CBT for relatively younger adult patients withMDS and sAML
has not yet been determined. In our study, the rate of
neutrophil engraftment was higher in the TBI  8 Gy þ Ara-
C þ CY group compared with the TBI  8 Gy þ other group,
suggesting that intensiﬁed conditioning was beneﬁcial in
terms of stable engraftment in CBT for relatively younger
adult patients with MDS and sAML.
The concomitant use of G-CSF and Ara-C during condi-
tioning may eliminate both recipient hematopoietic cells and
residual leukemic stem cells. In fact, 2 studies demonstrated
that the administration of G-CSF during conditioning
increased the engraftment of donor-derived cells in a mouse
bone marrow transplantation model [18,19]. In addition,
G-CSF administration enhanced the sensitivity to Ara-C in anAML xenotransplant model [28]. Nevertheless, a meta-
analysis demonstrated that the G-CSF priming effect during
chemotherapy did not improve survival in the clinical setting
of patients with AML and MDS [29]. In contrast, a meta-
analysis by Wei et al. reported that the Ara-C, aclarubicin,
and G-CSF (CAG) regimen was associated with a higher
remission rate in MDS and AML patients compared with a
non-CAG regimen [30]. On the other hand, previous reports
of Japanese single-institution studies demonstrated that a
conditioning regimen including G-CSFecombinedwith high-
dose Ara-C was safe and effective in allo-SCT using bone
marrow/peripheral blood from related and unrelated donors
for adult patients with AML and advanced MDS [31-35].
Recently, an encouraging report from China showed that
there was a lower relapse rate and better survival in patients
treated with G-CSFecombined conditioning compared with
those without G-CSF in haploidentical SCT for high-risk AML
[36]. Although a decreased relapse rate was observed in our
previous report of CBT for de novo AML [20], G-CSFecom-
bined conditioning was not associated with a decreased risk
of relapse in MDS and sAML in this study. Although the
reasons for these differences are unclear, 1 possible reason is
that the biological characteristics between MDS and de novo
AML are distinct. Because G-CSFecombined conditioning
contributed to enhanced neutrophil engraftment without
increasing the dose of TBI and chemotherapy, further studies
are warranted to evaluate the role of G-CSFecombined
reduced-intensity conditioning in older patients with MDS
and sAML.
The disease burden at CBT was associated with the
relapse and survival in our cohort. To reduce the disease
burden or to coordinate adult donors for allo-SCT, induction
chemotherapy or treatment with hypomethylating agents
before allo-SCT are often performed for MDS and sAML,
although the efﬁcacy of these treatments before allo-SCT has
not been demonstrated [37-40]. The administration of
chemotherapy before CBT had a negative impact on survival
and platelet engraftment in our cohort. This might be due, at
least in part, to the complication of infection without he-
matopoietic recovery. The use of cord blood as a graft source
enables patients with MDS and sAML to undergo allo-SCT as
an up-front treatment, without the need for time to coordi-
nate a donor. In this situation, intensiﬁed conditioning might
be effective, because most patients who never received
chemotherapy before conditioning have some tumor burden
at the time of allo-SCT.
To determinewhether G-CSFecombined conditioning has
more impact on survival for patients with a high tumor
burden, we analyzed a subgroup of patients with more than
5% bone marrow blasts at CBT. However, we were unable to
T. Konuma et al. / Biol Blood Marrow Transplant 21 (2015) 1632e1640 1639ﬁnd any impact of the G-CSFecombined conditioning on
survival in the multivariate analysis, possibly because of the
small sample size.
In conclusion, a G-CSFecombined conditioning regimen
was associated with signiﬁcantly higher neutrophil engraft-
ment and lower mortality in CBT for MDS and sAML. Based
on these data, we are currently planning a prospective ran-
domized study to test the role of the addition of a G-CSF
combination in a conditioning regimen for CBT in patients
with myeloid malignancies.
ACKNOWLEDGMENTS
This work was supported in part by Chugai Pharmaceu-
tical . The authors thank all of the physicians and staff at the
hospitals and the cord blood banks in Japan for their help in
this study and Maki Monna-Oiwa for her secretarial
assistance.
Financial disclosure: S.T. received research grants and
honoraria from Chugai Pharmaceuticals. The other authors
declare no competing ﬁnancial interests.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
Authorship statement: T.K. and S.T. designed the research,
performed transplantation, analyzed data, and wrote the
paper. All the other authors performed transplantation and
contributed to writing the paper. All authors approved the
ﬁnal version.
REFERENCES
1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;
383:2239-2252.
2. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and
treatment of primary myelodysplastic syndromes in adults: recom-
mendations from the European LeukemiaNet. Blood. 2013;122:
2943-2964.
3. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after trans-
plantation of cord blood or bone marrow from unrelated donors in
adults with leukemia. N Engl J Med. 2004;351:2265-2275.
4. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood
or bone marrow from unrelated donors in adults with acute leukemia.
N Engl J Med. 2004;351:2276-2285.
5. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of
unrelated bone marrow transplantation and cord blood transplantation
for adult patients with hematologic malignancies. Blood. 2004;104:
3813-3820.
6. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute
analysis of cord blood transplantation from unrelated donors with
bone marrow or peripheral blood stem-cell transplants from related
donors in adult patients with hematologic malignancies after mye-
loablative conditioning regimen. Blood. 2007;109:1322-1330.
7. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-speciﬁc analyses
of unrelated cord blood transplantation compared with unrelated bone
marrow transplantation in adult patients with acute leukemia. Blood.
2009;113:1631-1638.
8. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated
donor haemopoietic stem-cell transplantation in adults with acute
leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653-660.
9. Riddell S, Appelbaum FR, Buckner CD, et al. High-dose cytarabine and
total body irradiation with or without cyclophosphamide as a pre-
parative regimen for marrow transplantation for acute leukemia. J Clin
Oncol. 1988;6:576-582.
10. Mengarelli A, Iori A, Guglielmi C, et al. Standard versus alternative
myeloablative conditioning regimens in allogeneic hematopoietic stem
cell transplantation for high-risk acute leukemia. Haematologica. 2002;
87:52-58.
11. Kanda Y, Sakamaki H, Sao H, et al. Effect of conditioning regimen on the
outcome of bone marrow transplantation from an unrelated donor. Biol
Blood Marrow Transplant. 2005;11:881-889.
12. Inamoto Y, Nishida T, Suzuki R, et al. Signiﬁcance of additional high-
dose cytarabine in combination with cyclophosphamide plus total
body irradiation regimen for allogeneic stem cell transplantation. Bone
Marrow Transplant. 2007;39:25-30.
13. Miyauchi J, Kelleher CA, Wang C, et al. Growth factors inﬂuence the
sensitivity of leukemic stem cells to cytosine arabinoside in culture.
Blood. 1989;73:1272-1278.14. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recom-
mendations for the use of white blood cell growth factors: an
evidence-based clinical practice guideline. J Clin Oncol. 2006;24:
3187-3205.
15. Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with
granulocyte colony-stimulating factor on the outcome of chemo-
therapy for acute myeloid leukemia. N Engl J Med. 2003;349:743-752.
16. Büchner T, Berdel WE, Hiddemann W. Priming with granulocyte
colony-stimulating factorerelation to high-dose cytarabine in acute
myeloid leukemia. N Engl J Med. 2004;350:2215-2216.
17. Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming
with granulocyte colony-stimulating factor in remission induction of
acute myeloid leukemia restricted to dose escalation of cytarabine.
Blood. 2012;119:5367-5373.
18. Mardiney M 3rd, Malech HL. Enhanced engraftment of hematopoietic
progenitor cells in mice treated with granulocyte colony-stimulating
factor before low-dose irradiation: implications for gene therapy.
Blood. 1996;87:4049-4056.
19. Barese C, Pech N, Dirscherl S, et al. Granulocyte colony-stimulating
factor before nonmyeloablative irradiation decreases murine host he-
matopoietic stem cell function and increases engraftment of donor
marrow cells. Stem Cells. 2007;25:1578-1585.
20. Konuma T, Ooi J, Uchida N, et al. Granulocyte colony-stimulating factor
combined regimen in cord blood transplantation for acute myeloid
leukemia: a nationwide retrospective analysis in Japan. Haematologica.
2014;99:e264-e268.
21. Atsuta Y, Suzuki R, Yoshimi A, et al. Uniﬁcation of hematopoietic stem
cell transplantation registries in Japan and establishment of the TRUMP
System. Int J Hematol. 2007;86:269-274.
22. Bacigalupo A, Ballen K, Rizzo D, et al. Deﬁning the intensity of condi-
tioning regimens: working deﬁnitions. Biol Blood Marrow Transplant.
2009;15:1628-1633.
23. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for
evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:
2079-2088.
24. Atsuta Y, Kanda J, Takanashi M, et al. Different effects of HLA disparity
on transplant outcomes after single-unit cord blood transplantation
between pediatric and adult patients with leukemia. Haematologica.
2013;98:814-822.
25. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’
for medical statistics. Bone Marrow Transplant. 2013;48:452-458.
26. Robin M, Sanz GF, Ionescu I, et al. Unrelated cord blood transplantation
in adults with myelodysplasia or secondary acute myeloblastic leuke-
mia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia.
2011;25:75-81.
27. Sato A, Ooi J, Takahashi S, et al. Unrelated cord blood transplantation
after myeloablative conditioning in adults with advanced myelodys-
plastic syndromes. Bone Marrow Transplant. 2011;46:257-261.
28. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry elimi-
nates human leukemia stem cells in a mouse model of AML. Nat Bio-
technol. 2010;28:275-280.
29. Heuser M, Zapf A, Morgan M, et al. Myeloid growth factors in acute
myeloid leukemia: systematic review of randomized controlled trials.
Ann Hematol. 2011;90:273-281.
30. Wei G, Ni W, Chiao JW, et al. A meta-analysis of CAG (cytarabine,
aclarubicin, G-CSF) regimen for the treatment of 1029 patients with
acute myeloid leukemia and myelodysplastic syndrome. J Hematol
Oncol. 2011;4:46.
31. Takahashi S, Okamoto SI, Shirafuji N, et al. Recombinant human gly-
cosylated granulocyte colony-stimulating factor (rhG-CSF)-combined
regimen for allogeneic bone marrow transplantation in refractory
acute myeloid leukemia. Bone Marrow Transplant. 1994;13:239-245.
32. Takahashi S, Oshima Y, Okamoto S, et al. Recombinant human gran-
ulocyte colony-stimulating factor (G-CSF) combined conditioning
regimen for allogeneic bone marrow transplantation (BMT) in
standard-risk myeloid leukemia. Am J Hematol. 1998;57:303-308.
33. Okamoto S, Takahashi S, Wakui M, et al. Treatment of advanced
myelodysplastic syndrome with a regimen including recombinant
human granulocyte colony-stimulating factor preceding allogeneic
bone marrow transplantation. Br J Haematol. 1999;104:569-573.
34. Mori T, Aisa Y, Yokoyama A, et al. Total body irradiation and gran-
ulocyte colony-stimulating factor-combined high-dose cytarabine as a
conditioning regimen in allogeneic hematopoietic stem cell trans-
plantation for advanced myelodysplastic syndrome: a single-institute
experience. Bone Marrow Transplant. 2007;39:217-221.
35. Konuma T, Kato S, Ishii H, et al. Long-term outcomes of granulocyte
colony-stimulating factor-combined conditioning in allogeneic he-
matopoietic stem cell transplantation from HLA-identical family do-
nors for myeloid malignancies. Leuk Res. 2015;39:625-631.
36. Gao L, Wen Q, Chen X, et al. Effects of priming with recombinant hu-
man granulocyte colony-stimulating factor on conditioning regimen
for high-risk acute myeloid leukemia patients undergoing human
leukocyte antigen-haploidentical hematopoietic stem cell trans-
plantation: a multicenter randomized controlled study in southwest
China. Biol Blood Marrow Transplant. 2014;20:1932-1939.
T. Konuma et al. / Biol Blood Marrow Transplant 21 (2015) 1632e1640164037. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for
secondary acute myeloid leukemia: evaluation of transplantation as
initial therapy or following induction chemotherapy. Blood. 1997;89:
2578-2585.
38. Scott BL, Storer B, Loken MR, et al. Pretransplantation induction
chemotherapy and posttransplantation relapse in patients with
advanced myelodysplastic syndrome. Biol Blood Marrow Transplant.
2005;11:65-73.39. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy
before allogeneic hematopoietic stem cell transplantation from an
HLA-identical sibling donor for myelodysplastic syndrome. Leukemia.
2005;19:396-401.
40. Alessandrino EP, Della Porta MG, Pascutto C, et al. Should cytore-
ductive treatment be performed before transplantation in patients
with high-risk myelodysplastic syndrome? J Clin Oncol. 2013;31:
2761-2762.
